Lv3
268 积分 2023-06-02 加入
Activating mutations in the MET kinase domain co-occur with other driver oncogenes and mediate resistance to targeted therapy in NSCLC
5天前
待确认
Clinicopathological features and resistance mechanisms in HIP1‐ALK ‐rearranged lung cancer: A multicenter study
6天前
已完结
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial
1个月前
已完结
Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy
1个月前
已完结
Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy
1个月前
已完结
P1.06B.14 Optimal Cut-Off with NGS for Metamplification Andclinical Relevance to MET Inhibitor in Non-Small-Cell Lung Cancer
1个月前
已关闭
P1.06B.14 Optimal Cut-Off with NGS for Metamplification Andclinical Relevance to MET Inhibitor in Non-Small-Cell Lung Cancer
1个月前
已关闭
Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
1个月前
已完结
Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study
1个月前
已完结
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
1个月前
已完结
Mechanisms of catechol formation from aromatic compounds in isolated rat hepatocytes
皖公网安备34019202002308
